title: Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.
authors.forename: Leonidas
authors.initials: L
authors.lastname: Benetatos
authors.forename: Benetatos
authors.initials: B
authors.lastname: Leonidas
authors.forename: Aristeidis
authors.initials: A
authors.lastname: Chaidos
authors.forename: Chaidos
authors.initials: C
authors.lastname: Aristeidis
authors.forename: Vasiliki
authors.initials: V
authors.lastname: Alymara
authors.forename: Alymara
authors.initials: A
authors.lastname: Vasiliki
authors.forename: Amalia
authors.initials: A
authors.lastname: Vassou
authors.forename: Vassou
authors.initials: V
authors.lastname: Amalia
authors.forename: Konstantinos L
authors.initials: KL
authors.lastname: Bourantas
authors.forename: Bourantas L
authors.initials: BL
authors.lastname: Konstantinos
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction / Q000379:methods; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D004921:Erythropoietin; D013792:Thalidomide